Schond Greenway, MBA

Chief Financial Officer

Mr. Greenway joined MindMed in May 2022 after serving as CFO of Avalo Therapeutics, a precision medicine clinical stage biopharmaceutical company. He previously served as VP of Investor Relations at Mesoblast, an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. and in various roles at investment banking firms Morgan Stanley, Barclays Capital, and DURECT Corporation, predominantly focused on healthcare and technology. Mr. Greenway has participated in and advised on numerous transactions during his tenure in investment banking and capital markets. He has assisted in securing significant cumulative growth capital through a variety of equity and debt instruments in the public and private markets, as well as through funding from significant collaboration arrangements with therapeutics companies.

Mr. Greenway received an MBA from the Darden Graduate School of Business – University of Virginia and a BS from Florida A&M University.

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Schond Greenway, MBA

Chief Financial Officer

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Bridget Walton, MS

VP, Global Regulatory Affairs

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor